Saturday 17 October 2026
Export KRSA’s income statement to Excel — free account
Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
32.38
1.27
−3.77%
Follow KRSA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (98.22%) | (67.77%) | (39.34%) | (24.80%) |
+8 more TTM periods Free account |
|
| (82.29%) | (57.50%) | (36.07%) | (22.77%) | ||
ROIC |
(115.40%) | (105.93%) | (53.18%) | (45.69%) | |
Return on Tangible Assets |
2,550.19% | (366.13%) | (94.46%) | (52.51%) | |
Average Days of Receivables |
— | — | 175.99 | 12.78 | |
Free Cash Flow per Share |
(7.45) | (5.98) | (7.29) | (2.98) | |
Free Cash Flow |
(4.52) | (3.59) | (3.31) | (1.37) | |
Capital Expenditures |
(0.07) | (0.07) | — | — | |
| Other line items | |||||
Cash ROIC |
(69.84%) | (37.37%) | (26.89%) | (9.75%) | |
Accounts Receivable Turnover |
— | — | 2.67 | 39.65 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 46.24% | 17.37% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 293.54% | 209.88% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 21.26% | 16.39% | |
Operating CF/Net income |
0.66 | 0.67 | 0.94 | 0.63 | |
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Revenue per Share |
0.00 | 0.00 | 4.56 | 6.19 | |
Operating CF per Share |
(7.33) | (5.86) | (7.29) | (2.98) | |
Capex per Share |
(0.12) | (0.12) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates